AI
MYGN icon

Atria Investments’s Myriad Genetics MYGN Stock Holding History

Atria Investments’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.7K Buy
+14,654
New +$66.5K ﹤0.01% 2096
2025
Q2 		– Sell
-10,676
Closed -$94.7K – 2048
2025
Q1 		$94.7K Buy
+10,676
New +$128K ﹤0.01% 1875
2024
Q4 		– Sell
-11,414
Closed -$313K – 1938
2024
Q3 		$313K Buy
11,414
+581
+5% +$15.7K ﹤0.01% 1604
2024
Q2 		$265K Buy
+10,833
New +$238K ﹤0.01% 1661
2014
Q3 		– Sell
-53,944
Closed -$2.1M – 474
2014
Q2 		$2.1M Buy
+53,944
New +$2.01M 0.21% 96

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Atria Investments's MYGN Position: Q2 2026 in Review

Atria Investments opened a new position in Myriad Genetics (MYGN) in Q2 2026: 14,654 shares worth $83.7K. The stake represents ﹤0.01% of the portfolio and ranks #2096 among its holdings. This is a return to the name: Atria Investments previously reported a position in MYGN as recently as Q1 2025.

Atria Investments first reported a position in MYGN in Q2 2014 and has held it in 5 quarters since. The position peaked at $2.1M in Q2 2014. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Atria Investments held 14,654 shares of Myriad Genetics worth $83.7K as of Q2 2026.
  • Myriad Genetics was a new Atria Investments position in Q2 2026.
  • Myriad Genetics made up ﹤0.01% of Atria Investments's portfolio in Q2 2026, its #2096 holding.
  • Atria Investments first reported a position in Myriad Genetics in Q2 2014 and has held it in 5 quarters since.
  • Atria Investments's Myriad Genetics position peaked at $2.1M in Q2 2014.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.